id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2257-0008,FDA,FDA-2020-E-2257,Letter from FDA CDER TO U.S. Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2023-07-13T16:15:25Z,,0,0,0900006485ca0e8e
FDA-2020-E-2257-0006,FDA,FDA-2020-E-2257,Determination of Regulatory Review Period for Purposes of Patent Extension; XCOPRI,Notice,Determinations,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,2023-01-10T04:59:59Z,2022-11-10T02:00:38Z,2022-24457,0,0,090000648549d5cd
FDA-2020-E-2257-0005,FDA,FDA-2020-E-2257,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T19:04:08Z,,0,0,09000064852d0f6e
FDA-2020-E-2257-0004,FDA,FDA-2020-E-2257,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-10-12T04:00:00Z,2021,10,2021-10-12T04:00:00Z,,2021-10-12T18:19:41Z,,0,0,0900006484dc2b3d
FDA-2020-E-2257-0003,FDA,FDA-2020-E-2257,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-04-05T04:00:00Z,2021,4,2021-04-05T04:00:00Z,,2021-04-05T19:39:40Z,,0,0,0900006484a9acc7
FDA-2020-E-2257-0001,FDA,FDA-2020-E-2257,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-12-07T05:00:00Z,2020,12,2020-12-07T05:00:00Z,,2020-12-07T20:36:33Z,,0,0,090000648498ba0b
FDA-2020-E-2257-0002,FDA,FDA-2020-E-2257,"Patent Term Extension Application for XCOPRI® Patent No 7,598,279",Other,Application,2020-12-07T05:00:00Z,2020,12,2020-12-07T05:00:00Z,,2020-12-07T20:37:31Z,,0,0,090000648498ba0c